外科理论与实践

外科理论与实践 >

2025 , Vol. 30 >Issue 05: 456 - 460

DOI: https://doi.org/10.16139/j.1007-9610.2025.05.13

综述

晚期胃肠道间质瘤治疗的研究进展

  • 唐海啸 综述 ,
  • 张云 ,
  • 韩刚 ,
  • 龚航军 审校
展开
  • 上海中医药大学附属曙光医院胃肠外科，上海 201203

收稿日期: 2024-12-26

  网络出版日期: 2025-12-09

收起

Progression in treatment of advanced gastrointestinal stromal tumors

  • TANG Haixiao ,
  • ZHANG Yun ,
  • HAN Gang ,
  • GONG Hangjun
Expand
  • Department of Gastrointestinal Surgery, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Received date: 2024-12-26

  Online published: 2025-12-09

Fold

摘要

KIT或PDGFRA受体酪氨酸激酶功能获得性突变是大多数胃肠道间质瘤(GIST)的关键驱动因素。伊马替尼、舒尼替尼、安罗替尼、瑞戈非尼、瑞派替尼和阿伐替尼等酪氨酸激酶抑制剂的不断开发，极大程度上延长晚期GIST病人的总生存期。本文综述了近年来代表性酪氨酸激酶抑制剂在晚期胃肠道间质瘤治疗中的疗效(包括客观缓解率、疾病稳定率、中位无进展生存期)及常见不良事件，旨在为晚期GIST病人的治疗选择提供临床依据。

关键词： 胃肠道间质瘤; 酪氨酸激酶抑制剂; KIT原癌基因; 血小板衍生生长因子受体α

本文引用格式

唐海啸 综述 , 张云 , 韩刚 , 龚航军 审校 . 晚期胃肠道间质瘤治疗的研究进展[J]. 外科理论与实践, 2025 , 30(05) : 456 -460 . DOI: 10.16139/j.1007-9610.2025.05.13

Abstract

Gain-of-function mutations in KIT or PDGFRA receptor tyrosine kinase are key drivers of most gastrointestinal stromal tumor (GIST). The continuous development of tyrosine kinase inhibitors, such as imatinib, sunitinib, anlotinib, regorafenib, ripretinib and avapritinib, has greatly improved the overall survival of patients with advanced GIST. This article reviewed the efficacy (including objective response rate, disease stability rate, median progression free survival) and common adverse events of representative tyrosine kinase inhibitors in the treatment of advanced GIST in recent years, aiming to provide a clinical basis for the treatment options of patients with advanced GIST.

Key words： Gastrointestinal stromal tumor(GIST); Tyrosine kinase inhibitor(TKI); KIT proto-onco gene; Platelet-derived growth factor receptor alpha (PDGFRA)

参考文献

[1] KELLY C M, GUTIERREZ SAINZ L, CHI P. The management of metastatic GIST: current standard and investigational therapeutics[J]. J Hematol Oncol, 2021, 14(1):2.
[2] NAITO Y, NISHIDA T, DOI T. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours[J]. Gastric Cancer, 2023, 26(3):339-351.
[3] KHOSROYANI H M, KLUG L R, HEINRICH M C. TKI treatment sequencing in advanced gastrointestinal stromal tumors[J]. Drugs, 2023, 83(1):55-73.
[4] HUANG W K, WU C E, WANG S Y, et al. Systemic therapy for gastrointestinal stromal tumor: current standards and emerging challenges[J]. Curr Treat Options Oncol, 2022, 23(9):1303-1319.
[5] MECHAHOUGUI H, MICHAEL M, FRIEDLAENDER A. Precision oncology in gastrointestinal stromal tumors[J]. Curr Oncol, 2023, 30(5):4648-4662.
[6] MANTESE G. Gastrointestinal stromal tumor: epidemio-logy, diagnosis, and treatment[J]. Curr Opin Gastroenterol, 2019, 35(6):555-559.
[7] SERRANO C, MARTíN-BROTO J, ASENCIO-PASCUAL J M, et al. 2023 GEIS Guidelines for gastrointestinal stromal tumors[J]. Ther Adv Med Oncol, 2023,15: 17588359231192388.
[8] SHARMA A K, KIM T S, BAUER S, et al. Gastrointestinal stromal tumor: new insights for a multimodal approach[J]. Surg Oncol Clin N Am, 2022, 31(3):431-446.
[9] PANTALEO M A, URBINI M, SCHIPANI A, et al. SDHA germline variants in adult patients with SDHA-mutant gastrointestinal stromal tumor[J]. Front Oncol, 2022,11:778461.
[10] NAGANO H, OHYAMA S, SATO A, et al. Jejunal gastrointestinal stromal tumor that developed in a patient with neurofibromatosis type 1: a case report[J]. Diagn Pathol, 2023, 18(1):110.
[11] INOUE A, OTA S, YAMASAKI M, et al. Gastrointestinal stromal tumors: a comprehensive radiological review[J]. Jpn J Radiol, 2022, 40(11):1105-1120.
[12] UNK M, JEZER?EK NOVAKOVI? B, NOVAKOVI? S. Molecular mechanisms of gastrointestinal stromal tumors and their impact on systemic therapy decision[J]. Cancers (Basel), 2023, 15(5):1498.
[13] STRAUSS G, GEORGE S. Gastrointestinal stromal tumors[J]. Curr Oncol Rep, 2025, 27(3):312-321.
[14] NAPOLITANO A, THWAY K, SMITH M J, et al. KIT exon 9-mutated gastrointestinal sstromal tumours: biology and treatment[J]. Chemotherapy, 2022, 67(2):81-90.
[15] WOZNIAK A, RUTKOWSKI P, SCH?FFSKI P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a European multicenter analysis based on ConticaGIST[J]. Clin Cancer Res, 2014, 20(23):6105-6116.
[16] MOHAMMADI M, GELDERBLOM H. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib[J]. Expert Opin Investig Drugs, 2021, 30(2):143-152.
[17] MOHAMMADI M, IJZERMAN N S, HOLLANDER D D, et al. Improved efficacy of first-line imatinib in advanced gastrointestinal stromal tumors (GIST): the Dutch gist registry data[J]. Target Oncol, 2023, 18(3):415-423.
[18] CASALI P G, ABECASSIS N, ARO H T, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4):iv267.
[19] CHI P, QIN L X, CAMACHO N, et al. Phase Ⅰb trial of the combination of imatinib and binimetinib in patients with advanced gastrointestinal stromal tumors[J]. Clin Cancer Res, 2022, 28(8):1507-1517.
[20] CHI P, QIN L X, NGUYEN B, et al. Phase Ⅱ trial of imatinib plus binimetinib in patients with treatment-naive advanced gastrointestinal stromal tumor[J]. J Clin Oncol, 2022, 40(9):997-1008.
[21] VERSCHUUR A C, BAJ?IOVá V, MASCARENHAS L, et al. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase Ⅰ/Ⅱ trial[J]. Cancer Chemother Pharmacol, 2019, 84(1):41-50.
[22] REICHARDT P, DEMETRI G D, GELDERBLOM H, et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial[J]. BMC Cancer, 2016,16:22.
[23] SHEN G, ZHENG F, REN D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical deve-lopment[J]. J Hematol Oncol, 2018, 11(1):120.
[24] ZHOU Y, ZENG C, SUN X, et al. Activity of anlotinib in the second-line therapy of metastatic gastrointestinal stromal tumors: a prospective, multicenter, in vitro study[J]. Oncologist, 2023, 28(4):e191-e197.
[25] BR?I? I, ARGYROPOULOS A, LIEGL-ATZWANGER B. Update on molecular genetics of gastrointestinal stromal tumors[J]. Diagnostics (Basel), 2021, 11(2):194.
[26] MARTIN-BROTO J, VALVERDE C, HINDI N, et al. REGISTRI: Regorafenib in first-line of KIT/PDGFRA wild type metastatic GIST: a collaborative Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase Ⅱ trial[J]. Mol Cancer, 2023, 22(1):127.
[27] YEH C N, CHEN M H, CHEN Y Y, et al. A phase Ⅱ trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17[J]. Oncotarget, 2017, 8(27):44121-44130.
[28] BAUER S, JONES R L, BLAY J Y, et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): a randomized, open-label, phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(34):3918-3928.
[29] LI J, CAI S, ZHOU Y, et al. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors as a fourth- or later-line therapy: a multicenter, single-arm, open-label phase Ⅱ study[J]. Clin Cancer Res, 2022, 28(16):3425-3432.
[30] JONES R L, SERRANO C, VON MEHREN M, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase Ⅰ trial[J]. Eur J Cancer, 2021,145:132-142.
[31] JOSEPH C P, ABARICIA S N, ANGELIS M A, et al. Optimal avapritinib treatment strategies for patients with metastatic or unresectable gastrointestinal stromal tumors[J]. Oncologist, 2021, 26(4):e622-e631.
[32] LI J, ZHANG X, DENG Y, et al. Efficacy and safety of avapritinib in treating unresectable or metastatic gastrointestinal stromal tumors: a phase Ⅰ/Ⅱ, open-label, multicenter study[J]. Oncologist, 2023, 28(2):187-e114.
[33] SERRANO C, BAUER S, GóMEZ-PEREGRINA D, et al. Circulating tumor DNA analysis of the phase Ⅲ VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib[J]. Ann Oncol, 2023, 34(7):615-625.
[34] DEMETRI G D, VON MEHREN M, BLANKE C D, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7):472-480.
[35] HEINRICH M C, MAKI R G, CORLESS C L, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor[J]. J Clin Oncol, 2008, 26(33):5352-5359.
[36] DEMETRI G D, REICHARDT P, KANG Y K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863):295-302.
[37] KANG Y K, GEORGE S, JONES R L, et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase Ⅲ study[J]. J Clin Oncol, 2021, 39(28):3128-3139.
[38] HEINRICH M C, JONES R L, VON MEHREN M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial[J]. Lancet Oncol, 2020, 21(7):935-946.
Options
文章导航

/

〈 〉